The landscape of myeloma treatment is on the brink of an innovative overhaul as the potential of on-body delivery of Isatuximab garners burgeoning attention. The excitement is driven by the recent FDA approvals that underscore the effectiveness of anti-CD38 therapies in the treatment of newly diagnosed multiple myeloma patients. The regimens’ efficacy, coupled with the convenience of on-body delivery, could significantly disrupt the industry and potentially revolutionize the treatment paradigm.
Isatuximab, when used in combination with bortezomib, lenalidomide, and dexamethasone, has demonstrated promise for transplant-ineligible patients, while subcutaneous daratumumab has been approved for patients eligible for transplantation. The recent results from the PERSEUS and CEPHEUS trials provide a deeper understanding of these therapies’ effectiveness across different patient populations, indicating a robust and competitive landscape in myeloma treatment. Furthermore, the approval of Daratumumab with lenalidomide and dexamethasone for transplant-ineligible patients, as seen in the MAIA trial results, broadens the repertoire of available treatment options.
The phase 3 IRAKLIA trial results provide a glimmer of hope for Sanofi as it strives to regain its footing in the battle to deliver its anti-CD38 monoclonal antibody, isatuximab (Sarclisa). The trial data demonstrate the noninferiority of Sanofi’s on-body delivery system for isatuximab, compared with traditional IV administration. Patients in the trial overwhelmingly preferred the hands-free delivery option, indicating a high acceptance rate for this novel delivery method.
Moreover, the on-body delivery system for isatuximab, used to treat patients with multiple myeloma, mirrored the response rate and pharmacokinetics of the intravenous version, with a significantly reduced fraction of injection-site reactions. These compelling results, presented at the recent American Society of Clinical Oncology (ASCO) meeting, could trigger a reset in Sanofi’s bid for market share against Johnson & Johnson’s Darzelex Faspro, the subcutaneous formulation for daratumumab.
The IRAKLIA trial data, which were selected for Best of ASCO, are set to be published in ASCO’s flagship journal, the Journal of Clinical Oncology. The inclusion of this data in such a prestigious publication highlights the critical role of Isatuximab in the future of myeloma treatment.
Despite the positive trial data for isatuximab, used in various combinations to treat multiple myeloma, overcoming daratumumab’s significant advantage with subcutaneous delivery has been a challenge. However, the introduction of Enable Injections’ transfer design, which facilitates direct upload of therapy from a standard vial into the enFuse on-body delivery system, might prove to be a game-changer.
The advent of on-body delivery systems for anti-CD38 therapies is a testament to the pursuit of innovation in the biotech industry. It underscores the drive to place patients at the center of care, offering them more control over their treatment and potentially enhancing their quality of life. As we witness this groundbreaking shift, it’s evident that the future of myeloma treatment is on the cusp of a significant transformation.
Read more from ajmc.com
